We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

83 hedge funds and large institutions have $124M invested in UroGen Pharma in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 22 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

8% more funds holding

Funds holding: 77 → 83 (+6)

0% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 22

2.94% less ownership

Funds ownership: 65.68% → 62.75% (-2.9%)

12% less capital invested

Capital invested by funds: $140M → $124M (-$16.4M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $4K

Holders
83
Holders Change
+6
Holders Change %
+7.79%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
14
Increased
22
Reduced
22
Closed
7
Calls
–
Puts
$4K
Net Calls
-$4K
Net Calls Change
-$5K

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$2.1M
2
AIM
ARK Investment Management
Florida
+$1.15M
3
Millennium Management
Millennium Management
New York
+$697K
4
Bank of America
Bank of America
North Carolina
+$679K
5
Wells Fargo
Wells Fargo
California
+$648K

Top Sellers

Rank Fund Capital Flow
1
ZCA
Zeke Capital Advisors
Pennsylvania
-$3.23M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$2.26M
3
CBA
Coastal Bridge Advisors
Connecticut
-$281K
4
BlackRock
BlackRock
New York
-$213K
5
Barclays
Barclays
United Kingdom
-$160K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
76
Fidelity Investments
Massachusetts
$3K +$2.31K +296 New
PFS
77
Prospera Financial Services
Texas
$3K +$2.73K +350 New
QCG
78
Quadrant Capital Group
Ohio
$3K +$2.77K +355 New
Simplex Trading
79
Simplex Trading
Illinois
$2K +$678 +87 +44%
CAPTRUST Financial Advisors
80
CAPTRUST Financial Advisors
North Carolina
$2K +$1.82K +234 +1,232%
Carson Wealth (CWM LLC)
81
Carson Wealth (CWM LLC)
Nebraska
$1K +$866 +111 New
Macquarie Group
82
Macquarie Group
Australia
$8 – – –
Wellington Management Group
83
Wellington Management Group
Massachusetts
– -$2.26M -238,008 Closed
Group One Trading
84
Group One Trading
Illinois
– -$133K -14,036 Closed
Manulife (Manufacturers Life Insurance)
85
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$113 -11,924 Closed
ACM
86
Aquatic Capital Management
Illinois
– -$61K -6,410 Closed
JWA
87
JFS Wealth Advisors
Pennsylvania
– -$10K -1,000 Closed
US Bancorp
88
US Bancorp
Minnesota
– -$6K -605 Closed
CSWM
89
Cassady Schiller Wealth Management
Ohio
– -$1K -145 Closed
1 2 3
4

URGN Hedge Fund Activity: Q1 2022 in Review

83 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2022, worth a combined $124M — down 12% from $140M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new URGN positions and 7 closed out — a net gain of 7 holders — while 22 added to existing stakes and 22 trimmed.

The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $2.1M. The largest seller was Zeke Capital Advisors, cutting an estimated $3.23M.

  • 83 institutional investors held UroGen Pharma (URGN) as of Q1 2022, up from 77 in Q4 2021.
  • Funds reported $124M of UroGen Pharma stock for Q1 2022, down 12% quarter-over-quarter.
  • 14 funds opened new UroGen Pharma positions in Q1 2022 and 7 closed out, a net change of +7 holders.
  • The largest UroGen Pharma buyer in Q1 2022 was Stonepine Capital Management, an estimated $2.1M added.
  • The largest UroGen Pharma seller in Q1 2022 was Zeke Capital Advisors, an estimated $3.23M sold.

Based on aggregated 13F filings for Q1 2022.